Chloe Kent
Chloe is an award-winning journalist who has specialized in health reporting throughout her career, with a particular focus on women's health and access to medicine. Before joining Generics Bulletin she worked for B2B publishing consortium Verdict, writing about medical technology and pharmaceuticals. Having graduated from the University of York, she went on to train as a journalist with the Press Association.
Latest From Chloe Kent
EU Must Stop Offshoring Of Essential Medicines, Say Trade Groups
Current EU policy discourages the domestic manufacturing of essential medicines, say Medicines for Europe and the European Fine Chemicals Group. The associations have called for “immediate, robust and ambitious” policy change to drive manufacturing back home.
Endo Partners With US Government On Critical Medicines
Endo subsidiary Par Sterile Products will expand its Rochester, Michigan facility to begin the fill-finish manufacturing of both mRNA and adenovirus vaccines. Around three-quarters of the project’s expected $120m total costs are being funded by the US government as part of larger efforts to boost the country’s domestic supply of essential medicines.
Zydus Mounts Challenge To Novartis With Generic Nelarabine Injection
Zydus Cadila’s single-dose nelarabine injection (250mg/50ml) will enjoy 180 days of competitive generic therapy market exclusivity following approval from the US FDA, as the first approved rival to Novartis’ Arranon brand.
Sawai Maintains Strong Domestic Performance, Continues To Flounder In US
Sawai’s Q2 results mirrored those of Q1, with a strong performance in Japan but a weak one in the US. The firm is continuing to focus on establishing new production facilities in both territories.
AAM Speaks Out Against Build Back Better Bill
The US Association for Accessible Medicines has panned the Biden administration’s Build Back Better Act, which it says threatens patient access to affordable drugs in its current form.
Advanz Appoints Stada Europe Head As New CEO
Stada’s head of Europe, Steffen Wagner, is set to become the new CEO of Advanz early next year, while current CEO Graeme Duncan will step down and take a new role as special advisor to the board. Advanz is also appointing a new chief financial officer, with Merck Healthcare’s Andreas Stickler set to succeed Adeel Ahmad in January.